Literature DB >> 11447212

Interaction of farnesylated PRL-2, a protein-tyrosine phosphatase, with the beta-subunit of geranylgeranyltransferase II.

X Si1, Q Zeng, C H Ng, W Hong, C J Pallen.   

Abstract

Protein of regenerating liver (PRL)-1, -2, and -3 comprise a subgroup of closely related protein-tyrosine phosphatases featuring a C-terminal prenylation motif conforming to either the consensus sequence for farnesylation, CAAX, or geranylgeranylation, CCXX. Yeast two-hybrid screening for PRL-2-interacting proteins identified the beta-subunit of Rab geranylgeranyltransferase II (betaGGT II). The specific interaction of betaGGT II with PRL-2 but not with PRL-1 or -3 occurred in yeast and HeLa cells. Chimeric PRL-1/-2 molecules were tested for their interaction with betaGGT II, and revealed that the C-terminal region of PRL-2 is required for interaction, possibly the PRL variable region immediately preceeding the CAAX box. Additionally, PRL-2 prenylation is prequisite for betaGGT II binding. As prenylated PRL-2 is localized to the early endosome, we propose that this is where the interaction occurs. PRL-2 is not a substrate for betaGGT II, as isoprenoid analysis showed that PRL-2 was solely farnesylated in vivo. Co-expression of the alpha-subunit (alpha) of GGT II, betaGGT II, and PRL-2 resulted in alpha/betaGGT II heterodimer formation and prevented PRL-2 binding. Expression of PRL-2 alone inhibited the endogenous alpha/betaGGT II activity in HeLa cells. Together, these results indicate that the binding of alphaGGT II and PRL-2 to betaGGT II is mutually exclusive, and suggest that PRL-2 may function as a regulator of GGT II activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11447212     DOI: 10.1074/jbc.M010400200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Cellular localization of PRL-1 and PRL-2 gene expression in normal adult human tissues.

Authors:  Carmen M Dumaual; George E Sandusky; Pamela L Crowell; Stephen K Randall
Journal:  J Histochem Cytochem       Date:  2006-09-06       Impact factor: 2.479

2.  Tissue-specific alterations of PRL-1 and PRL-2 expression in cancer.

Authors:  Carmen M Dumaual; George E Sandusky; Han Weng Soo; Sean R Werner; Pamela L Crowell; Stephen K Randall
Journal:  Am J Transl Res       Date:  2012-01-05       Impact factor: 4.060

3.  A combination of metabolic labeling and 2D-DIGE analysis in response to a farnesyltransferase inhibitor facilitates the discovery of new prenylated proteins.

Authors:  Charuta C Palsuledesai; Joshua D Ochocki; Todd W Markowski; Mark D Distefano
Journal:  Mol Biosyst       Date:  2014-05

4.  Association of differentially expressed genes with activation of mouse hepatic stellate cells by high-density cDNA microarray.

Authors:  Xiao-Jing Liu; Li Yang; Feng-Ming Luo; Hong-Bin Wu; Qu Qiang
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

5.  Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice.

Authors:  Ke Guo; Jing Ping Tang; Li Jie; Abdul Qader O Al-Aidaroos; Cheng William Hong; Cheng Peow Bobby Tan; Jung Eun Park; Leyon Varghese; Zhiwei Feng; Jianbiao Zhou; Wee Joo Chng; Qi Zeng
Journal:  Oncotarget       Date:  2012-02

6.  Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.

Authors:  Ju-Dong Lee; Haiyoung Jung; Sang-Hyun Min
Journal:  Exp Ther Med       Date:  2016-09-20       Impact factor: 2.447

7.  Expression of phosphatase of regenerating liver family genes during embryogenesis: an evolutionary developmental analysis among Drosophila, amphioxus, and zebrafish.

Authors:  Ming-Der Lin; Hsun-Tzu Lee; Szu-Chieh Wang; Han-Ru Li; Hsin-Lun Hsien; Kai-Wen Cheng; Yu-Di Chang; Min-Lang Huang; Jr-Kai Yu; Yau-Hung Chen
Journal:  BMC Dev Biol       Date:  2013-05-04       Impact factor: 1.978

8.  Functionally enhanced placenta-derived mesenchymal stem cells inhibit adipogenesis in orbital fibroblasts with Graves' ophthalmopathy.

Authors:  Jae Yeon Kim; Sohae Park; Hyun-Jung Lee; Helen Lew; Gi Jin Kim
Journal:  Stem Cell Res Ther       Date:  2020-11-05       Impact factor: 6.832

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.